$SYRE
Spyre Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000163628223000018 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.07M $8.580M
YoY Change 177.06% 23.42%
% of Gross Profit
Research & Development $33.68M $24.66M
YoY Change 136.35% 105.89%
% of Gross Profit
Depreciation & Amortization $4.000K $0.00
YoY Change -98.96% -100.0%
% of Gross Profit
Operating Expenses $47.75M $18.34M
YoY Change 147.05% -3.13%
Operating Profit -$18.34M
YoY Change -2.23%
Interest Expense $4.126M -$24.11M
YoY Change 906.34% -8471.53%
% of Operating Profit
Other Income/Expense, Net -$21.39M -$21.77M
YoY Change 66750.0% -7076.6%
Pretax Income -$63.18M -$40.10M
YoY Change 236.35% 117.45%
Income Tax $0.00 $3.000K
% Of Pretax Income
Net Earnings -$63.18M -$40.11M
YoY Change 235.67% 119.96%
Net Earnings / Revenue
Basic Earnings Per Share -$9.34
Diluted Earnings Per Share -$4.02 -$9.34
COMMON SHARES
Basic Shares Outstanding 4.049M shares 101.2M
Diluted Shares Outstanding 4.294M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $339.3M $203.6M
YoY Change 508.99% 176.34%
Cash & Equivalents $188.9M $90.59M
Short-Term Investments $150.4M $113.0M
Other Short-Term Assets $2.251M $2.200M
YoY Change -63.53% -72.06%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $341.5M $205.9M
YoY Change 448.57% 150.49%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $0.00
YoY Change -100.0% -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $9.000K $9.000K
YoY Change -98.68% -98.8%
Total Long-Term Assets $331.0K $1.316M
YoY Change -96.28% -85.92%
TOTAL ASSETS
Total Short-Term Assets $341.5M $205.9M
Total Long-Term Assets $331.0K $1.316M
Total Assets $341.9M $207.3M
YoY Change 380.52% 126.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.48M $21.50M
YoY Change 2481.98% 414.6%
Accrued Expenses $13.11M $15.90M
YoY Change -2.51% 22.35%
Deferred Revenue $0.00 $0.00
YoY Change -100.0% -100.0%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.98M $44.87M
YoY Change 118.19% 153.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $41.31M $20.70M
YoY Change
Total Long-Term Liabilities $41.31M $20.70M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $31.98M $44.87M
Total Long-Term Liabilities $41.31M $20.70M
Total Liabilities $73.29M $65.56M
YoY Change 251.69% 173.05%
SHAREHOLDERS EQUITY
Retained Earnings -$764.4M -$701.2M
YoY Change 79.61% 72.37%
Common Stock $763.2M $456.0M
YoY Change 60.34% -3.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $184.0M -$245.4M
YoY Change
Total Liabilities & Shareholders Equity $341.9M $207.3M
YoY Change 380.52% 126.36%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$63.18M -$40.11M
YoY Change 235.67% 119.96%
Depreciation, Depletion And Amortization $4.000K $0.00
YoY Change -98.96% -100.0%
Cash From Operating Activities -$31.04M -$34.59M
YoY Change 71.11% 129.56%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$35.27M -$97.63M
YoY Change -351.95% -691.7%
Cash From Investing Activities -$35.27M -$97.63M
YoY Change -351.95% -691.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 163.6M -12.53M
YoY Change -2045187.5% 9538.46%
NET CHANGE
Cash From Operating Activities -31.04M -34.59M
Cash From Investing Activities -35.27M -97.63M
Cash From Financing Activities 163.6M -12.53M
Net Change In Cash 97.29M -144.8M
YoY Change -2445.56% -11226.06%
FREE CASH FLOW
Cash From Operating Activities -$31.04M -$34.59M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$31.04M -$34.59M
YoY Change 71.11% 129.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://aegleabio.com/20230930#DevelopmentFeeAndRoyaltyMember
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://aegleabio.com/20230930#DevelopmentFeeAndRoyaltyMember
CY2022Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://aegleabio.com/20230930#DevelopmentFeeAndRoyaltyMember
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://aegleabio.com/20230930#DevelopmentFeeAndRoyaltyMember
CY2023Q3 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
163000 usd
CY2022Q4 us-gaap Nontrade Receivables Current
NontradeReceivablesCurrent
375000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2187000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6172000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
205949000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
62258000 usd
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1307000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1553000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
0 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3220000 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3430000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
683000 usd
CY2023Q3 us-gaap Assets
Assets
207265000 usd
CY2022Q4 us-gaap Assets
Assets
71144000 usd
CY2023Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1678000 usd
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
677000 usd
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
7510000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
625000 usd
CY2023Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
517000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15861000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12837000 usd
CY2023Q3 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
19823000 usd
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
0 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
44872000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14656000 usd
CY2023Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
20690000 usd
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
0 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4004000 usd
CY2023Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2179000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
65562000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
20839000 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
8913659 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2614014 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2614014 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
7000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
6000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
455957000 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
475971000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-132000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-48000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701234000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-425624000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-245402000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
207265000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
71144000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
886000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2161000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
174000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
886000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2161000 usd
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
24660000 usd
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
11977000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
55822000 usd
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
44328000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8584000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6952000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25874000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
23452000 usd
CY2023Q3 agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
-298000 usd
CY2022Q3 agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130188000 usd
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
CY2023Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
CY2022Q3 us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
18337000 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
18929000 usd
us-gaap Operating Expenses
OperatingExpenses
197275000 usd
us-gaap Operating Expenses
OperatingExpenses
67780000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18337000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-18755000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-196389000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-65619000 usd
CY2023Q3 us-gaap Investment Income Net
InvestmentIncomeNet
1251000 usd
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
288000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
2021000 usd
us-gaap Investment Income Net
InvestmentIncomeNet
427000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2342000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
24000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2262000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
25000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-21767000 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
312000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-79247000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
452000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40104000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18443000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-275636000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65167000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-209000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-26000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-174000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275610000 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.84
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-20.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-20.17
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3767918 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3767918 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3961546 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3961546 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3222987 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3222987 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40107000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000 usd
us-gaap Net Income Loss
NetIncomeLoss
-275610000 usd
us-gaap Net Income Loss
NetIncomeLoss
-64993000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-29000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-38000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-87000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-83000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-77000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40250000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18198000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-275694000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65157000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
50305000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
18000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
3768000 usd
CY2023Q2 agle Contingent Value Right Distribution To Common Stockholders
ContingentValueRightDistributionToCommonStockholders
-29500000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1775000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
18000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-217081000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-207369000 usd
CY2023Q3 agle Stock Issued During Period Value Options Exercised And Employee Stock Ownership Plan
StockIssuedDuringPeriodValueOptionsExercisedAndEmployeeStockOwnershipPlan
105000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2112000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-29000 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-114000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-40107000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-245402000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83941000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
184000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2101000 usd
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-13000 usd
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-120000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24436000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
61657000 usd
CY2022Q2 agle Stock Issued During Period Value Common Stock And Pre Funded Warrants Registered Direct Offering
StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsRegisteredDirectOffering
42873000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2017000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-36000 usd
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-31000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-22323000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
84157000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-8000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
38000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1566000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-38000 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
74000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-18234000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
67555000 usd
us-gaap Profit Loss
ProfitLoss
-275610000 usd
us-gaap Profit Loss
ProfitLoss
-64993000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
744000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1182000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8405000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
5684000 usd
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
130188000 usd
agle Acquired In Process Research And Development
AcquiredInProcessResearchAndDevelopment
0 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
14609000 usd
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
0 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
2580000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-915000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
220000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
292000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
612000 usd
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
175000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-351000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3310000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2863000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1001000 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
859000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
575000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-897000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-212000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-146000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2326000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-297000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4000000 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1293000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-2115000 usd
us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68874000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-62004000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
3035000 usd
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
0 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
15000000 usd
us-gaap Proceeds From Sale Of Intangible Assets
ProceedsFromSaleOfIntangibleAssets
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
38000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
475000 usd
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
112631000 usd
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
35000000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
21000000 usd
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
78046000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-73121000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
43008000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
197364000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 usd
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
0 usd
agle Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net Of Offering Costs
ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNetOfOfferingCosts
42874000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
123000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
222000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
16000 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
410000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
197471000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
42686000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-152000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
55483000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23538000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36416000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16980000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91899000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40518000 usd
us-gaap Stock Issued1
StockIssued1
189741000 usd
us-gaap Stock Issued1
StockIssued1
0 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701200000 usd
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
203600000 usd
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
CY2023Q2 agle Number Of Employees Retained
NumberOfEmployeesRetained
10 employee
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets, liabilities, and equity and the amount of revenues and expenses. Actual results could differ significantly from those estimates. The most significant estimates and assumptions that management considers in the preparation of the Company's financial statements relate to the valuation of consideration transferred in acquiring IPR&amp;D; the discount rate, probabilities of success, and timing of estimated cash flows in the valuation of the CVR liability; inputs used in the Black-Scholes model for stock-based compensation expense; estimated future cash flows used in calculating the impairment of right-of-use lease assets; and estimated cost to complete performance obligations related to revenue recognition. The consideration transferred in acquiring IPR&amp;D in connection with the acquisition of Spyre was comprised of shares of the Company’s common stock and shares of Series A Preferred Stock. To determine the fair value of the equity transferred, the Company considered the per share value of the PIPE, which was an over-subscribed financing event involving a group of accredited investors.</span></div>
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 usd
CY2023Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
72362000 usd
CY2023Q3 agle Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
3000 usd
CY2023Q3 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
0 usd
CY2023Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
72365000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
113121000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000 usd
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
115000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
113007000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
26007000 usd
CY2022Q4 agle Cash Equivalents Unrealized Gains
CashEquivalentsUnrealizedGains
1000 usd
CY2022Q4 agle Cash Equivalents Unrealized Losses
CashEquivalentsUnrealizedLosses
3000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
26005000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
20877000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
2000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
31000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20848000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
97193000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
115000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
97193000 usd
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
115000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
25166000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
34000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
25166000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
34000 usd
CY2023Q3 agle Number Of Domestic Banking Institutions
NumberOfDomesticBankingInstitutions
3 bank
CY2023Q2 us-gaap Asset Acquisition Consideration Transferred
AssetAcquisitionConsiderationTransferred
113200000 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
102518000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
20848000 usd
CY2023Q3 agle Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
10489000 usd
CY2022Q4 agle Debt Securities Available For Sale Fair Value Maturity Allocated And Single Maturity Date After Year One
DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOne
0 usd
CY2023Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
113007000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
20848000 usd
CY2023Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
5368000 usd
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4589000 usd
CY2023Q3 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
6669000 usd
CY2022Q4 agle Accrued Contracted Research And Development Costs
AccruedContractedResearchAndDevelopmentCosts
6972000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3484000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
946000 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
340000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
330000 usd
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
15861000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
12837000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
694892 shares
CY2022Q2 agle Class Of Warrant Or Right Offering Price Of Warrants Or Rights
ClassOfWarrantOrRightOfferingPriceOfWarrantsOrRights
39.9975
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0025
CY2022Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42900000 usd
CY2022Q2 agle Placement Agent Fees And Offering Costs
PlacementAgentFeesAndOfferingCosts
2100000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0025
agle Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised
OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercised
0.0499
agle Ownership Percentage For Outstanding Warrants To Purchase Shares Of Common Stock To Be Exercised To Certain Holders
OwnershipPercentageForOutstandingWarrantsToPurchaseSharesOfCommonStockToBeExercisedToCertainHolders
0.0999
agle Class Of Warrant Or Right Revised Ownership Percentage Period To Take Effect After Notice
ClassOfWarrantOrRightRevisedOwnershipPercentagePeriodToTakeEffectAfterNotice
P61D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1044667 shares
CY2023Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
14.50
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
50806 shares
CY2022Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3867366 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
153686 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
52.50
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4785000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1565000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8405000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5684000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2696000 usd
agle Contract With Customer Liability Additions
ContractWithCustomerLiabilityAdditions
575000 usd
us-gaap Contract With Customer Liability Increase Decrease For Contract Acquired In Business Combination
ContractWithCustomerLiabilityIncreaseDecreaseForContractAcquiredInBusinessCombination
-3271000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
0 usd
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2022Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0 usd
CY2023Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.83
us-gaap Severance Costs1
SeveranceCosts1
6400000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
4500000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
1000000 usd
CY2023Q2 us-gaap Disposal Group Including Discontinued Operation Consideration
DisposalGroupIncludingDiscontinuedOperationConsideration
500000 usd
CY2023Q2 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
900000 usd
CY2023Q2 us-gaap Impairment Of Leasehold
ImpairmentOfLeasehold
1700000 usd
CY2023Q3 agle Operating Lease Termination Fee Amount
OperatingLeaseTerminationFeeAmount
2000000 usd
CY2023Q2 agle Other Commitment Right To Terminate Agreement Or Work Order Prior Written Notice Period
OtherCommitmentRightToTerminateAgreementOrWorkOrderPriorWrittenNoticePeriod
P30D
CY2023Q2 agle Other Commitment Right To Terminate Work Order Reasonable Cause Prior Written Notice Period
OtherCommitmentRightToTerminateWorkOrderReasonableCausePriorWrittenNoticePeriod
P6M
CY2023Q2 agle Other Commitment Right To Terminate Work Order By Counterparty Reasonable Cause Termination Amount Payable
OtherCommitmentRightToTerminateWorkOrderByCounterpartyReasonableCauseTerminationAmountPayable
0 usd
CY2023Q2 agle Other Commitment Right To Terminate Work Order Material Breach Uncured Period
OtherCommitmentRightToTerminateWorkOrderMaterialBreachUncuredPeriod
P30D
CY2023Q2 agle Other Commitment Right To Terminate Work Order Unusual Or Infrequent Cause Period
OtherCommitmentRightToTerminateWorkOrderUnusualOrInfrequentCausePeriod
P90D
CY2023Q2 agle Other Commitment Non Refundable License Fee Amount
OtherCommitmentNonRefundableLicenseFeeAmount
200000 usd
CY2023Q2 agle Other Commitment Royalty Percentage
OtherCommitmentRoyaltyPercentage
0.01
CY2023Q2 agle Other Commitment Right To Terminate Agreement Prior Written Notice Period
OtherCommitmentRightToTerminateAgreementPriorWrittenNoticePeriod
P6M
CY2023Q2 agle Other Commitment Right To Terminate Agreement By Counterparty Material Breach Uncured Period
OtherCommitmentRightToTerminateAgreementByCounterpartyMaterialBreachUncuredPeriod
P60D
CY2023Q2 agle Other Commitment Right To Terminate Agreement By Counterparty Payments Not Received Period
OtherCommitmentRightToTerminateAgreementByCounterpartyPaymentsNotReceivedPeriod
P30D

Files In Submission

Name View Source Status
agle-20230930_cal.xml Edgar Link unprocessable
0001636282-23-000018-index-headers.html Edgar Link pending
0001636282-23-000018-index.html Edgar Link pending
0001636282-23-000018.txt Edgar Link pending
0001636282-23-000018-xbrl.zip Edgar Link pending
agle-20230930.htm Edgar Link pending
agle-20230930.xsd Edgar Link pending
agle-20230930xex311.htm Edgar Link pending
agle-20230930xex312.htm Edgar Link pending
agle-20230930xex321.htm Edgar Link pending
agle-20230930_g1.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
agle-20230930_def.xml Edgar Link unprocessable
agle-20230930_lab.xml Edgar Link unprocessable
agle-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
agle-20230930_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending